arrow
N

Nicolas De Schryver

clinique saint pierre
H指数:16
被引数:1,470

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Short-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial

短疗程、高剂量β-内酰胺类药物治疗与常规剂量和疗程在危重患者中的比较:HIT-HARD试验方案——一项III期多中心、整群随机、交叉、非劣效性试验

2026-11-120
OAAI
Pharmacokinetics, pharmacodynamics and safety of TIN816 in patients with sepsis-associated acute kidney injury: results from a randomized Phase 2a study

TIN816的药代动力学、药效动力学及安全性研究:一项随机Ⅱa期试验的结果

2025-10-010
PRE
Immunological sub-phenotypes and response to convalescent plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial
2024-10-210
OAAI
Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients
2023-10-2631
OAAI
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, aTREM-1 inhibitor, in patients with septic shock (ASTONISH) : a double-blind, randomised, controlled, phase 2b trial

aTREM-1抑制剂nangibotide在脓毒症休克患者中的疗效,安全性和最佳生物标志物富集策略的前瞻性评估 (ASTONISH): 一项双盲,随机,对照,2b期试验

2023-10-0119
OAAI
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
2022-11-1532
OAAI